about
Autophagy in cancerActivating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly.Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.Anti-proliferation effects of Sirolimus sustained delivery film in rabbit glaucoma filtration surgery.TGFβ-induced deptor suppression recruits mTORC1 and not mTORC2 to enhance collagen I (α2) gene expression.Rapamycin-induced G1 cell cycle arrest employs both TGF-β and Rb pathwaysTarget of rapamycin (TOR) in nutrient signaling and growth controlRapamycin decreases airway remodeling and hyperreactivity in a transgenic model of noninflammatory lung disease.Molecular imaging with activatable reporter systemsCombined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.Mutations in critical domains confer the human mTOR gene strong tumorigenicity.Phosphatidic acid and lipid-sensing by mTORMechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs.mTOR function and therapeutic targeting in breast cancer.Profiling mTOR pathway in neuroendocrine tumors.Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer.Implementing personalized cancer genomics in clinical trials.Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitationsmTOR signaling and its roles in normal and abnormal brain development.mTOR in health and in sickness.Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies.Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma.Considerations on mTOR regulation at serine 2448: implications for muscle metabolism studies.Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors.TORC1-mediated sensing of chaperone activity alters glucose metabolism and extends lifespan.Control of leucine-dependent mTORC1 pathway through chemical intervention of leucyl-tRNA synthetase and RagD interaction.Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.HTLV-1 HBZ positively regulates the mTOR signaling pathway via inhibition of GADD34 activity in the cytoplasm.Structural biology: Security measures of a master regulator.Complete genomic landscape of a recurring sporadic parathyroid carcinoma.The Suppression of Wound Healing Response with Sirolimus and Sunitinib Following Experimental Trabeculectomy in a Rabbit Model.Rapamycin attenuates pathological hypertrophy caused by an absence of trabecular formation.
P2860
Q26999216-8C4A6277-9E4F-48C6-9DD7-6FE103E2C255Q27852954-1B3A001E-1147-443D-9392-73DE5E8D1520Q30647055-BF1B94E2-6338-4E50-B48D-712BEC6869C0Q33917547-91186CBD-E941-44C7-8668-A498294EB324Q35234108-9B76A408-0AAE-4D4F-A341-24C1E92768EFQ35255044-628EF076-0AC9-4E49-8CDB-C3130F3D80F4Q35354812-4CD66BF6-0D7D-4A64-B8E1-05A377DC1BFCQ35555383-C036757E-FCF6-49B1-B7C8-C484C3D98DC1Q35620394-1B7F6471-C331-493C-B46C-49FC38A16785Q35789958-469A03AE-4D13-45E6-99D5-FE91977B15E7Q35915786-C73B66DF-C2E5-4E26-B602-F622ABD1446BQ36535062-4DC6F80B-B05A-468B-8621-7772AEB6529FQ36647365-ACED8B8D-1C9D-4DF0-91F7-3E90DEED5B54Q36893382-1AEB8B36-FA8C-4733-A358-B633C291A9C8Q37217474-F361D8C6-680D-41D4-AB24-F7CE87605986Q37724947-FDA92297-D8E2-489A-B3DF-33FC273831BCQ37743486-E5C868B6-6630-414F-8B51-7F404D07BBC7Q38034440-C0114B59-CFF7-4F61-ACE5-94AA13A35F72Q38042638-29AB4C62-1035-4228-977A-A1D259C26640Q38102920-E40EC3C9-F7D1-48FD-B761-29FF98EDECF7Q38208069-2E957824-0615-403A-AAC3-52CFD0C139AEQ38209310-86D31391-6A68-407D-BD3B-7FAAFEE97694Q38590634-53204B71-562B-4659-A56D-2A126019CDB5Q38793867-54673485-2368-4CBA-9403-01A53C3763C0Q39013913-498AE429-451D-4AE7-BDD3-35A2DDAC89D9Q39144817-26182DDF-FD2A-419C-A5CE-317C00521E1BQ40975849-B3C198AA-A9EB-41C8-AFE2-68D4255EB8BDQ41628978-F60C9479-166A-466D-8D79-04CBBE07205BQ42015481-4CCE4474-2A1C-46DB-A27A-ABCEBB829DF1Q42364996-56218E20-DA10-461F-8DF4-C63D0F45E164Q42818886-FD22F3F9-77FC-4F07-9F8D-D4D9CFB26D0BQ46470339-91A08FFE-7878-49A7-9284-A899D138C155Q51042797-C84ED8BD-FF0F-4A44-9F19-B1811EBF3CBFQ53535205-6F84652A-95C9-42F4-A1E2-7D6F685E27D7Q55188606-2046CB64-CFDC-4F77-88AF-69B9B749FB68
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Activating mutations of TOR (target of rapamycin).
@ast
Activating mutations of TOR (target of rapamycin).
@en
type
label
Activating mutations of TOR (target of rapamycin).
@ast
Activating mutations of TOR (target of rapamycin).
@en
prefLabel
Activating mutations of TOR (target of rapamycin).
@ast
Activating mutations of TOR (target of rapamycin).
@en
P2093
P2860
P1433
P1476
Activating mutations of TOR (target of rapamycin).
@en
P2093
Fuyuhiko Tamanoi
Molly Hardt
Naphat Chantaravisoot
P2860
P304
P356
10.1111/J.1365-2443.2010.01482.X
P577
2011-01-07T00:00:00Z